- PROFESSOR Medicine, Infectious Diseases
American Board of Internal Medicine
Mount Sinai School of Medicine
Mount Sinai School of Medicine
- Donna Mildvan, M.D., Professor of Medicine, Icahn School of Medicine at Mount Sinai; formerly Professor of Medicine, Albert Einstein College of Medicine; Co-Principal Investigator/Principal Investigator, AIDS Clinical Trials Group (1987-2008); Chief, Infectious Diseases and AIDS Divisions and Director of AIDS Research at Mount Sinai Beth Israel (formerly Beth Israel Medical Center). Responsible for early descriptions of AIDS and complications of HIV infection, including the lymphadenopathy syndrome, and collaborations demonstrating LAV (HIV) in the first US AIDS cases and the first convincing evidence that the brain harbored and could transmit HIV. Focus has been on antiretroviral drug development, innovation in biomarker research and study design, championing ways to improve diversity in clinical trials participation, and optimizing management of community acquired pneumonia. Led the ACTG’s trial A5073 on directly observed antiretroviral therapy, co-chaired the Surrogate Markers Collaborative Group, has been site PI for the NIAID-sponsored “Addressing Health Disparities in AIDS Clinical Trials, Project ACT.” Chair of numerous study protocols, and member of numerous NIH review committees, including the NIAID AIDS Charter Review Committee. Consultant to the FDA, CDC. Developed an algorithm for HIV biomarker validation which has achieved broad recognition and applicability in disciplines outside the field of HIV. Chaired and reconfigured the ACTG’s Underrepresented Populations Committee (2002-2008) to concentrate on increasing minority access to clinical trials. Longstanding interest in community acquired pneumonia, membership on the national Pneumonia Technical Expert Panel since 2010, design of and participation in multisite studies aimed at new drug development for CAP, as well as contributions to single site studies addressing antimicrobial prescribing and its impact on the emergence of drug resistance.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Mildvan during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Cempra Pharmaceuticals; Janssen Scientific Affairs, LLC
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.